How the Liver Metabolizes Peptide Drugs: Comparing Laboratory Models
Comparison of human liver S9, hepatocyte spheroids, and other in vitro systems for predicting peptide drug metabolism revealed important differences relevant to peptide therapeutic development.
Quick Facts
What This Study Found
Comparison of human liver S9, hepatocyte spheroids, and other in vitro systems revealed model-dependent differences in peptide metabolism prediction, informing best practices for peptide drug development.
Key Numbers
4 peptides (cyclosporine, leuprorelin, desmopressin, cetrorelix); S9 most metabolites for 2; CYP-dependent metabolism found; hydrolytic similar across systems
How They Did This
In vitro metabolism study comparing multiple hepatic models for peptide degradation. Human liver S9 fractions and hepatocyte spheroids evaluated.
Why This Research Matters
Better liver metabolism prediction for peptides means more accurate dosing, fewer clinical failures, and faster drug development for the growing class of peptide therapeutics.
The Bigger Picture
As peptide therapeutics proliferate, understanding their hepatic metabolism becomes increasingly important. Selecting the right in vitro model early in development can prevent costly clinical failures.
What This Study Doesn't Tell Us
In vitro models may not fully replicate in vivo liver metabolism. Limited number of peptide compounds tested. Inter-individual variability in human liver not fully captured.
Questions This Raises
- ?Which liver model most accurately predicts peptide drug half-life in humans?
- ?Can in vitro metabolism data reliably predict peptide dosing intervals?
- ?Do modified peptides (PEGylated, lipidated) follow the same metabolic patterns?
Trust & Context
- Key Stat:
- Model choice matters Different liver models gave different peptide metabolism predictions — choosing the right model is crucial for accurate peptide drug development
- Evidence Grade:
- Moderate evidence: systematic comparison of established in vitro liver models.
- Study Age:
- Published 2021.
- Original Title:
- Hepatic in vitro metabolism of peptides; Comparison of human liver S9, hepatocytes and Upcyte hepatocytes with cyclosporine A, leuprorelin, desmopressin and cetrorelix as model compounds.
- Published In:
- Journal of pharmaceutical and biomedical analysis, 196, 113921 (2021)
- Authors:
- Jyrkäs, Juha, Tolonen, Ari
- Database ID:
- RPEP-05476
Evidence Hierarchy
Frequently Asked Questions
Why does liver metabolism matter for peptide drugs?
The liver breaks down peptide drugs, determining how long they last in the body. Understanding this process helps drug developers design peptides that stay active long enough to work (like once-weekly semaglutide) rather than being quickly degraded.
Why test different liver models?
Different laboratory liver systems can give different metabolism predictions. Finding which model best matches what actually happens in the human body helps researchers make better decisions during drug development.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-05476APA
Jyrkäs, Juha; Tolonen, Ari. (2021). Hepatic in vitro metabolism of peptides; Comparison of human liver S9, hepatocytes and Upcyte hepatocytes with cyclosporine A, leuprorelin, desmopressin and cetrorelix as model compounds.. Journal of pharmaceutical and biomedical analysis, 196, 113921. https://doi.org/10.1016/j.jpba.2021.113921
MLA
Jyrkäs, Juha, et al. "Hepatic in vitro metabolism of peptides; Comparison of human liver S9, hepatocytes and Upcyte hepatocytes with cyclosporine A, leuprorelin, desmopressin and cetrorelix as model compounds.." Journal of pharmaceutical and biomedical analysis, 2021. https://doi.org/10.1016/j.jpba.2021.113921
RethinkPeptides
RethinkPeptides Research Database. "Hepatic in vitro metabolism of peptides; Comparison of human..." RPEP-05476. Retrieved from https://rethinkpeptides.com/research/jyrkas-2021-hepatic-in-vitro-metabolism
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.